China Universal Asset Management Co., Ltd. Corvus Pharmaceuticals, Inc. Transaction History
China Universal Asset Management Co., Ltd.
- $1.03 Billion
- Q2 2025
A detailed history of China Universal Asset Management Co., Ltd. transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 15,488 shares of CRVS stock, worth $113,372. This represents 0.01% of its overall portfolio holdings.
Number of Shares
15,488
Previous 12,889
20.16%
Holding current value
$113,372
Previous $40,000
52.5%
% of portfolio
0.01%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding CRVS
# of Institutions
101Shares Held
38.9MCall Options Held
98.5KPut Options Held
226K-
Orbimed Advisors LLC San Diego, CA7.17MShares$52.4 Million1.02% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct7.04MShares$51.6 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.28MShares$24 Million0.0% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$24 Million9.69% of portfolio
-
Rtw Investments, LP New York, NY2.68MShares$19.6 Million0.16% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $341M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...